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1. INTRODUCTION {#mgg3871-sec-0005}
===============

Breast cancer is the most common malignant tumor in women worldwide (Bray et al., [2018](#mgg3871-bib-0001){ref-type="ref"}). The occurrence of breast cancer is thought to be the result of the interaction of genetic and nongenetic factors. Recent studies have shown that different molecular subtypes of breast cancer have different genetic variables, which may indicate that different subtypes of breast cancer have different etiological pathways (Garcia‐Closas et al., [2008](#mgg3871-bib-0008){ref-type="ref"}; Stacey et al., [2007](#mgg3871-bib-0019){ref-type="ref"}). Traditional prognostic factors, such as tumor size, grade, and lymph node metastasis status, are still the most important prognostic factors for breast cancer. However, little interpretations of genetic information were included in the prognosis. As a relatively small allele variable, SNPs has a higher availability, and linkage disequilibrium exists among different populations and races, so it can be used as an important medium for studying different diseases or disease characteristics. With the development of GWAS, an increasing number of genetic variables have been confirmed to be associated with breast cancer. Studies about SNPs are currently focused on the correlation between clinicopathological features, DFS, overall survival (OS), and loci. Some researchers have even combined multiple gene locus models with clinicopathological features to forecast patients' prognosis. However, their significances for patients or mechanism of pathogenesis remain unknown.

Our early work confirmed that SNP rs3803662 (TOX3/TNRC9) increased the risk of breast cancer in Henan Han population in a case--control study (He et al., [2016](#mgg3871-bib-0011){ref-type="ref"}). This study was designed to analyze the correlation between five SNPs which were confirmed by GWAS (rs10069690 \[TERT\], rs2046210 \[6q25.1\], rs2981582 \[FGFR2\], rs889312 \[MAP3K1\], rs3803662\[TOX3/TNRC9\]) (Dai et al., [2012](#mgg3871-bib-0004){ref-type="ref"}; Han et al., [2011](#mgg3871-bib-0009){ref-type="ref"}; Hein et al., [2012](#mgg3871-bib-0013){ref-type="ref"}; Mulligan et al., [2011](#mgg3871-bib-0016){ref-type="ref"}; Palmer et al., [2013](#mgg3871-bib-0017){ref-type="ref"}) and DFS of female breast cancer in Henan Han patients.

2. MATERIALS AND METHODS {#mgg3871-sec-0006}
========================

2.1. Ethical compliance {#mgg3871-sec-0007}
-----------------------

The ethics committee of the Medical Ethics Committee of Henan Cancer Hospital approved the study, and informed consent was obtained from all patients prior to their enrollment in the study. The ethical review number is 2015ct072.

2.2. Subjects {#mgg3871-sec-0008}
-------------

In total, 232 female patients with invasive breast cancer who were treated in Affiliated Tumor Hospital of Zhengzhou University between 1 January 2014 and 31 May 2014, were enrolled in this study. Only subjects from Henan Han population were included in this study, furthermore, the subjects were required to have no family history of tumors or genetic diseases and to have received no neoadjuvant therapy. Among them, six patients were diagnosed as breast cancer with distant metastasis, and two patients were partially missing clinical information. All cases were confirmed by histopathology with information available about ER, PR, HER2, and Ki67. Details of patient characteristics were listed in Table [1](#mgg3871-tbl-0001){ref-type="table"}.

###### 

Patient demographic and disease characteristics

  Characteristic                                           *n* (%)
  -------------------------------------------------------- -------------
  No. of patients                                          232
  Age                                                      
  \<50 years                                               128 (55.17)
  ≥50 years                                                103 (44.40)
  Unknown                                                  1 (0.43)
  Tumor size                                               
  T1                                                       88 (37.93)
  T2                                                       119 (51.29)
  T3                                                       17 (7.33)
  T4                                                       6 (2.59)
  Unknown                                                  2 (0.86)
  Number of metastatic lymph nodes                         
  N0                                                       130 (56.03)
  N1                                                       54 (23.28)
  N2                                                       27 (11.64)
  N3                                                       19 (8.19)
  Unknown                                                  2 (0.86)
  ER and PR status                                         
  Positive                                                 165 (71.12)
  Negative                                                 67 (28.88)
  HER2 status                                              
  Negative                                                 161 (69.40)
  Positive                                                 69 (29.74)
  Unknown                                                  2 (0.86)
  Menstrual status[a](#mgg3871-note-0003){ref-type="fn"}   
  Premenopausal                                            148 (63.79)
  Postmenopausal                                           82 (35.34)
  Unknown                                                  2 (0.86)

Abbreviations: T1, Tumor ≤20 mm or less in greatest dimension; T2, Tumor \>20 mm but ≤50 mm in greatest dimension; T3, Tumor \>50 mm in greatest dimension; T4, Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules) N0, No regional lymph node metastasis histologically; N1, Metastases to movable ipsilateral level I, II axillary lymph node(s); N2, Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases; N3, Metastases in ipsilateral infraclavicular (level III axillary) lymph node(s) with or without level I, II axillary lymph node involventment; or in clinically detected ipsilateral interal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvment.

determining menopause includes any of the following: (a) prior bilateral oophorectomy; (b) age ≥60 years; (c) age \<60 years and amenorrheic for 12 or more months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression and follicle‐stimulating hormone (FSH) and estradiol in the postmenopausal range.
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2.3. Genotyping and quality control {#mgg3871-sec-0009}
-----------------------------------

In this study, we selected SNPs with minor allele frequency \>5% from the Han Chinese population in Beijing (CHB) in the HapMap database (<http://www.hapmap.org>). Chinese keywords \"single nucleotide polymorphisms\", \"breast cancer\", \"hormone receptor status\", \"molecular subtype\", \"prognosis\", and English keywords \"SNPs\", \"breast cancer\", \"ER\", \"PR\", \"subtypes of breast cancer\", \"prognosis\", \"GWAS\" were used as keywords to search in PubMed, Embase, China knowledge Network, cqvip, Wanfang Database, and Chinese Biomedical Literature Database for Chinese and foreign literature. Eventually, we selected five SNPs (rs10069690 \[TERT\], rs2046210 \[6q25.1\], rs2981582 \[EGFR2\], rs889312 \[MAP3K1\], and rs3803662 \[TOX3\]/\[TNRC9\]). All DNA samples were blindly duplicated to assess the reproducibility of genotypes. An average reproducibility of 100% was obtained. The mean call rate in the final data set was 99% for SNPs; the quality evaluation is listed in Table [2](#mgg3871-tbl-0002){ref-type="table"} ([2016](#mgg3871-bib-0011){ref-type="ref"}). DNA was isolated from peripheral blood samples at the Central Laboratory of Henan Tumor Hospital using whole blood genomic DNA extraction kits (TianGen, M2023). DNA samples were stored at −80°C before genotyping. The genotyping of SNPs was carried out by Shanghai Genesky Bio‐Tech Co., Ltd. (<http://biotech.geneskies.com/index.html>) using the improved multiplex ligase detection reaction (iMLDR) method; the primers are listed in Table [3](#mgg3871-tbl-0003){ref-type="table"}.

###### 

Quality evaluation

  SNP          Call rate (%)   Test for HWE (*p* value)   MAF (the study)   MAF (Hapmap‐HCB)           
  ------------ --------------- -------------------------- ----------------- ------------------ ------- ---
  rs10069690   99.5            .36                        0.192             T                  0.202   T
  rs2046210    99.82           .18                        0.393             A                  0.380   A
  rs2981582    99.83           .13                        0.368             A                  0.336   A
  rs3803662    99.83           .38                        0.314             G                  0.347   G
  rs889312     99.83           .20                        0.494             C                  0.500   A

Abbreviations: SNPs, single‐nucleotide polymorphisms; HWE, Hardy--Weinberg equilibrium; MAF, minor allele frequency.
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###### 

SNPs and PCR primer

  SNPs         Chr   Chromosome position   Gene        PCR primer
  ------------ ----- --------------------- ----------- -------------------------------------
  rs10069690   5     1279790               TERT        rs10069690F: CCCAGCTTCCTCAGACCCTGTT
                                                       rs10069690R: CTGGATCCGTGTCCTGCTGTG
  rs2046210    6     151948366             --          rs2046210F: GAGGTGTGACCACTGCCATCGT
                                                       rs2046210R: GAAACCATCAGGGTGCCTCAAC
  rs2981582    10    123352317             FGFR2       rs2981582F: GAGGCTGGGCTCTCTGTCCTCT
                                                       rs2981582R: GAACCTCTCTCCCAGCCCTTTG
  rs3803662    16    52586341              LOC643714   rs3803662F: GGTGGGGGTCAGTCCACAGTTT
                                                       rs3803662R: TGCTGCTAGTCCTTGGCTGTTC
  rs889312     5     56031884              --          rs889312F: TTCCAGTCTGGGGTGGCTTGTA
                                                       rs889312R: TGGGAAGGAGTCGTTGAGTTTTCA

Abbreviations: SNPs, single‐nucleotide polymorphisms; PCR, polymerase chain reaction; F, forward; R, reverse.
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2.4. Statistical analysis and outcome measures {#mgg3871-sec-0010}
----------------------------------------------

Disease‐free survival(DFS) was defined as the elapsed time between the date of initial treatment (surgery) and the first date of documented disease recurrence or death due to breast cancer. Follow‐up information was obtained by telephone and outpatient data. The information included patient\'s status (alive; death; local recurrence; distant metastasis), results of clinical physical examinations, and imaging data (color Doppler ultrasound, CT, whole body bone imaging or MRI). Clinical prognostic indicators included the age of onset, tumor size, lymph node metastasis status, and subtypes of breast cancer. Kaplan--Meier analysis and the log‐rank test were used to identify the correlation between DFS and clinical prognostic indicators as well as five SNPs. The factors which were significant in univariate analysis were then analyzed in the multivariate Cox proportional hazards model to determine the independent prognostic factor. All statistical procedures were performed with SPSS (version 20.0; SPSS Company, Chicago, IL). All*p* values reported were two‐sided and were calculated at a significance level of .05.

2.5. Construction and optimization of regulatory network {#mgg3871-sec-0011}
--------------------------------------------------------

Gene ontology functional annotation and KEGG analysis of selected genes were carried out. In GO analysis, the screening conditions of AmiGO (<http://geneontology.org>) were "name of selected genes" and"Homo sapiens". GO functional annotation of selected genes was preliminarily analyzed. For KEGG analysis of breast cancer‐related genes, the first step was that entering the homepage of KEGG signaling pathway database (<http://www.kegg.jp/kegg/pathway.html>). Screening condition organism was \"hsa\", keywords were \"names of selected genes\" and \"Breast cancer\". Queried the regulatory network of breast cancer related genes. Bayesian algorithm was used to optimize the regulatory network model to find out the most possible pathway of gene regulation of breast cancer cell proliferation by probability.

3. RESULTS {#mgg3871-sec-0012}
==========

The final analysis included 209 patients with breast invasive cancer. The follow‐up deadline was 31 December 2017 and the median follow‐up length was 44.5 months. There were 23 (11.0%) DFS events. Four patients had regional recurrence, 19 had distant metastasis (five had regional recurrence synchronously accompanied by distant metastasis). No patient died due to breast cancer. There were 15 (7.18%) cases who were not interviewed (listed in Table [4](#mgg3871-tbl-0004){ref-type="table"}). The survival curve is shown in Figure [1](#mgg3871-fig-0001){ref-type="fig"}.

###### 

Events of all patients

  Events                                        Number of events
  --------------------------------------------- ------------------
  Only regional recurrence                      4
  Distance recurrence                           19
  Distance recurrence and regional recurrence   5
  Only distance recurrence                      14
  Death caused by any recurrence of disease     0
  Total                                         23
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![Kaplan--Meier curves of DFS for 209 patients](MGG3-7-e871-g001){#mgg3871-fig-0001}

The results of the Kaplan--Meier analysis showed that tumor size, lymph node metastasis status, and subtypes of breast cancer were significantly associated with DFS (*p *= .024, .000, .028) (Table [5](#mgg3871-tbl-0005){ref-type="table"}). There were no associations between SNPs rs10069690 (TERT), rs2046210 (6q25.1), rs2981582 (FGFR2) and rs889312 (MAP3K1) and DFS (*p *= .202, .096, .686, .172), but SNP rs3803662 (TOX3/TNRC9) had association with DFS (*p *= .010) (Table [6](#mgg3871-tbl-0006){ref-type="table"}). The multivariate Cox proportional hazards model showed that lymph node metastasis status and SNP rs3803662 (TOX3/TNRC9) were correlated with DFS. Compared with GA/AA, GG increased the recurrent risk of breast cancer (*p *= .021, HR = 2.914) (Table [7](#mgg3871-tbl-0007){ref-type="table"}). The results of GO analysis showed that gene TOX3/TNRC9 had three functions: biological_process, molecular_function, and cellular_component (Table [8](#mgg3871-tbl-0008){ref-type="table"}). According to KEGG signaling pathway database, the map of breast cancer‐related gene regulatory network was obtained (Figure [2](#mgg3871-fig-0002){ref-type="fig"}). The optimal pathway of breast cancer cell regulatory network in which TOX3/TNRC9 was involved was selected by Bayesian theorem optimization (Figure [3](#mgg3871-fig-0003){ref-type="fig"}).

###### 

Survival analysis by Kaplan--Meier analysis and log‐rank test between clinicopathological factors and DFS

  Clinicopathological factors     No. of patients   Events (%)   Log Rank (Mantel‐Cox)   
  ------------------------------- ----------------- ------------ ----------------------- -------
  Age                                                                                    
  \<50 years                      120               15 (12.5)    0.606                   .436
  ≥50 years                       89                8 (9.0)                               
  Tumor size                                                                             
  T1 + T2                         189               18 (9.5)     5.113                   .024
  T3 + T4                         20                5 (25.0)                              
  No. of metastatic lymph nodes                                                          
  N0 + N1                         173               11 (6.4)     55.425                  0.000
  N2                              22                4 (18.2)                              
  N3                              14                8 (57.1)                              
  Subtypes                                                                               
  L‐A                             20                0 (0.0)      4.846                   0.028
  L‐B                             97                8 (8.2)                               
  L‐H                             31                4 (12.9)                              
  HER2                            32                7 (21.8)                              
  TNBC                            29                4 (13.8)                              

Abbreviations: T1, Tumor ≤20 mm or less in greatest dimension; T2, Tumor \>20 mm but ≤50 mm in greatest dimension; T3, Tumor \>50 mm in greatest dimension; T4, Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules) N0, No regional lymph node metastasis histologically; N1, Metastases to movable ipsilateral level I, II axillary lymph node(s); N2, Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases; N3, Metastases in ipsilateral infraclavicular (level III axillary) lymph node(s) with or without level I, II axillary lymph node involventment; or in clinically detected ipsilateral interal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvment; L‐A, Luminal A; L‐B, Luminal B (not contains) L‐H, Luminal‐HER2; HER2:HER2‐enrich; TNBC:triple‐negative breast cancer.
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###### 

Survival analysis by Kaplan--Meier analysis and log‐rank test between SNPs and DFS

  SNPs         No. of patients   Events (%)   Log Rank (Mantel--Cox)   
  ------------ ----------------- ------------ ------------------------ ------
  rs10069690                                                           
  TT           8                 2 (25.0)     1.629                    .202
  CT + CC      201               21 (10.4)                              
  rs2046210                                                            
  GG           70                11 (15.7)    2.765                    .096
  GA + GG      139               12 (8.6)                               
  rs2981582                                                            
  AA           34                3 (8.8)      0.163                    .686
  GA + GG      175               20 (11.4)                              
  rs3803662                                                            
  GG           29                7 (24.1)     6.703                    .010
  GA + AA      180               16 (8.8)                               
  rs889312                                                             
  CC           49                8 (16.3)     1.866                    .172
  CA + AA      160               15 (9.4)                               

Abbreviation: SNPs, single‐nucleotide polymorphisms.
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###### 

Multivariate Cox proportional hazards model for DFS in the study cohort

  Variables                                      HR       95% CI          *p*
  ---------------------------------------------- -------- --------------- ------
  Age: ≥50 years versus \<50 years (reference)   1.304    0.535--3.175    .559
  T: T3 + T4 versus T1 + T2 (reference)          1.897    0.679--5.302    .222
  No. of metastatic lymph nodes                                           
  N2 versus N0 + N1 (reference)                  3.505    1.099--11.182   .034
  N3 versus N0 + N1 (reference)                  18.277   7.254--46.053   .000
  Subtypes                                                                
  L‐HER2 + HER2 versus L‐A + L‐B (reference)     1.506    0.568--3.991    .411
  TNBC versus L‐A + L‐B (reference)              2.038    0.594--6.993    .258
  rs3803662: GG versus GA + AA (reference)       2.914    1.1733--7.239   .021

Abbreviations: CI, confidence interval; HR, hazard ratio; T1, Tumor ≤20 mm or less in greatest dimension; T2, Tumor \>20 mm but ≤50 mm in greatest dimension; T3, Tumor \> 50 mm in greatest dimension; T4, Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules) N0, No regional lymph node metastasis histologically; N1, Metastases to movable ipsilateral level I, II axillary lymph node(s); N2, Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases; N3, Metastases in ipsilateral infraclavicular (level III axillary) lymph node(s) with or without level I, II axillary lymph node involventment; or in clinically detected ipsilateral interal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvment; L‐A, Luminal A; L‐B, Luminal B (not contains) L‐H, Luminal‐HER2; HER2, HER2‐enrich; TNBC, triple‐negative breast cancer.

John Wiley & Sons, Ltd

###### 

The result of GO Analysis about Gene TOX3/TNRC9

  Genes        Name                                                                    Gene ontology        GO number
  ------------ ----------------------------------------------------------------------- -------------------- ------------
  TOX3/TNRC9   Estrogen response element binding                                       Biological_process   GO:0000107
               DNA binding                                                             Biological_process   GO:0000104
               DNA‐binding transcription factor activity, RNA polymerase II‐specific   Molecular_function   GO:0000113
               Nucleus                                                                 Cellular_component   GO:0000039
               Regulation Of transcription by RNA polymerase II                        MOLECULAR_function   GO:0000981
               Apoptotic process                                                       Biological_process   GO:0007177
               Protein homodimerization activity                                       Molecular_function   GO:1901185
               Regulation of apoptotic process                                         Biological_process   GO:0008185
               Positive regulation of transcription, DNA‐templated                     Biological_process   GO:0038095
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![Regulation Network of Breast Cancer‐related genes contained GeneTOX3/TNRC9](MGG3-7-e871-g002){#mgg3871-fig-0002}

![Optimized breast cancer cell regulatory network contained Gene TOX3/TNRC9 by Bayesian networks](MGG3-7-e871-g003){#mgg3871-fig-0003}

4. DISCUSSION {#mgg3871-sec-0013}
=============

Breast cancer is the most common malignant tumor in Chinese women (Li et al., [2018](#mgg3871-bib-0015){ref-type="ref"}). In recent years, with the improvement of comprehensive treatment, the survival of breast cancer patients has greatly improved, but 20%--30% of patients still have recurrence and metastasis (Cameron et al., [2017](#mgg3871-bib-0002){ref-type="ref"}; Pan et al., [2017](#mgg3871-bib-0018){ref-type="ref"}). Currently, clinicopathological factors determining the prognosis of patients mainly include lymph node staging, tumor size, molecular subtype, and so on, but these factors still cannot accurately evaluate the prognosis of patients. There are many studies on correlations between SNPs and prognosis of breast cancer, but conclusions are different. Some researchers believed that rs88931 (MAP3K1) was highly correlated with distant disease‐free survival (DDFS), DFS, and OS of hormone receptor‐positive breast cancer (Kuo et al., [2017](#mgg3871-bib-0014){ref-type="ref"}). Yamamoto‐Ibusuki et al. ([2015](#mgg3871-bib-0022){ref-type="ref"}) confirmed that homozygous alleles of rs2046210 showed worse relapse‐free survival. Hein et al. ([2017](#mgg3871-bib-0012){ref-type="ref"}) showed that rs2981582 (FGFR2), rs889312 (MAP3K1), and rs3803662 (TOX3) did not affect the overall survival and progression‐free survival in breast cancer patients. Similar finding was noted in the current study, but the role of rs3803662 in the prognosis of breast cancer patients in Han population was rarely analyzed. Our study explored genetic factors related to the prognosis of female breast cancer patients in Henan by means of SNPs (a third‐generation genetic marker) which have regional and ethnic differences. We identified SNPs rs10069690 (TERT), rs2046210 (6q25.1), rs2981582 (FGFR2), and rs889312 (MAP3K1) were not associated with DFS, while rs3803662 (TOX3/TNRC9) was associated with DFS. Genotype GG of rs3803662 (TOX3/TNRC9) was associated with a worse prognosis and increased the recurrent risk of breast cancer nearly threefold. This locus was an independent prognostic factor in this study population, which was consistent with foreign studies (Fasching et al., [2012](#mgg3871-bib-0007){ref-type="ref"}).

At the same time, combined with our previous research results (He et al., [2016](#mgg3871-bib-0011){ref-type="ref"}), we believe that gene TOX3 plays a certain role in the occurrence and development of breast cancer in Henan Han women. TOX3 gene in malignant tumors has been reported to be mainly involved in the transcription process (Dittmer et al., [2010](#mgg3871-bib-0005){ref-type="ref"}; Yahata et al., [2001](#mgg3871-bib-0021){ref-type="ref"}; Yuan, Qiu, & Ghosh, [2009](#mgg3871-bib-0023){ref-type="ref"}). Studies about breast cancer showed that TOX3 was an anti‐oncogene (Cowper‐Sal·lari et al., [2012](#mgg3871-bib-0003){ref-type="ref"}), and was expressed more in luminal tumors (Han, Zhang, Zheng, Huo, & Olopade, [2016](#mgg3871-bib-0010){ref-type="ref"}). These studies confirmed the roles of TOX3 in breast cancer, but how to regulates is complex and unknown (Cowper‐Sal·lari et al., [2012](#mgg3871-bib-0003){ref-type="ref"}; Han et al., [2016](#mgg3871-bib-0010){ref-type="ref"}; Yu & Li, [2015](#mgg3871-bib-0020){ref-type="ref"}).

Recently, with the continuous development of bioinformatics, a large number of multifunctional bioinformatics softwares have emerged and they have greatly accelerated the integration and utilization of existing biomedical data. Bioinformatics research helps us to find the most reasonable and effective methods or approaches for treatment and prevention of diseases (Ethier, Desautels, Templeton, Shah, & Amir, [2017](#mgg3871-bib-0006){ref-type="ref"}). We used tools of bioinformatics, such as GO, KEGG, and Bayesian networks to analyze TOX3. We found TOX3/TNRC9 had three functions: molecular_function, cellular_component, and biological_process by GO analysis. IGF‐IGF1R‐PI3K‐Akt‐mTOR‐S6K was the best possible pathway for the differentiation of breast cancer cells by KEGG analysis and ER‐TOX3/TNRC9 was the best possible pathway for the survival of tumor cells by Bayesian networks. These results provide a theoretical basis for targeted therapy of breast cancer, and further lay the theoretical foundation for studies of mechanisms of TOX3 gene in breast cancer.

Several limitations of this study should be acknowledged. First, the number of SNPs tested was limited to five, which is not a sufficient evaluation of the correlation between the GWAS‐identified SNPs and prognosis of breast cancer. Second, the sample size was too small to definitively evaluate outcomes of breast cancer, and the study needs to be replicated in a larger sample. We need to further verify the mechanism or the regulatory network in the real world (cells, animals, or populations).

In summary, these findings provide further evidence that some genetic factors are strongly associated with breast cancer prognosis among the Han Population. These differences may be due to racial differences. The main purpose of the gene regulatory network is to obtain a network of interactions between genes, and to reveal the overall or partial network characteristics related to life processes. Understanding the mechanism of life activity at the molecular level is conducive to the study of cell function and life process, thus providing directions for exploring the causes of human diseases.

5. CONCLUSIONS {#mgg3871-sec-0014}
==============

SNP rs3803662 (TOX3/TNRC9) is an independent prognostic factor for breast cancer in Henan Han Population. ER‐TOX3/TNRC9 is the best possible pathway involved in the pathogenesis of breast cancer.
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